Quercetin as a possible complementary agent for early-stage COVID-19 : Concluding results of a randomized clinical trial
Copyright © 2023 Di Pierro, Khan, Iqtadar, Mumtaz, Chaudhry, Bertuccioli, Derosa, Maffioli, Togni, Riva, Allegrini, Recchia and Zerbinati..
Background: Quercetin, a natural polyphenol with demonstrated broad-spectrum antiviral, anti-inflammatory, and antioxidant properties, has been proposed as an adjuvant for early-stage coronavirus disease 2019 (COVID-19) infection. Objective: To explore the possible therapeutic effect of quercetin in outpatients with early-stage mild to moderate symptoms of COVID-19. Methods: This was an open-label randomized controlled clinical trial conducted at the department of medicine, King Edward Medical University, Lahore, PK. Patients were randomized to receive either standard of care (SC) plus an oral quercetin supplement (500 mg Quercetin Phytosome®, 1st week, TDS: 2nd week, BDS) (n = 50, quercetin group) or SC alone (n = 50, control group). Results: After one week of treatment, patients in the quercetin group showed a speedy recovery from COVID-19 as compared to the control group, i.e., 34 patients (vs. 12 in the control group) tested negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (p = 0.0004), and 26 patients (vs. 12 in the control group) had their COVID-19-associated acute symptoms resolved (p = 0.0051). Patients in the quercetin group also showed a significant fall in the serum lactate dehydrogenase (LDH) mean values i.e., from 406.56 ± 183.92 to 257.74 ± 110.73 U/L, p = 0.0001. Quercetin was well-tolerated by all the 50 patients, and no side effects were reported. Conclusion: Our results, suggest the possible therapeutic role of quercetin in early-stage COVID-19, including speedy clearance of SARS-CoV-2, early resolution of the acute symptoms and modulation of the host's hyperinflammatory response. Clinical Trial Registration: clinicaltrials.gov, identifier NCT04861298.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in pharmacology - 13(2022) vom: 23., Seite 1096853 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Di Pierro, Francesco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3CL protease inhibition |
|---|
| Anmerkungen: |
Date Revised 02.02.2023 published: Electronic-eCollection ClinicalTrials.gov: NCT04861298 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fphar.2022.1096853 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35223086X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35223086X | ||
| 003 | DE-627 | ||
| 005 | 20231226053238.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2022.1096853 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM35223086X | ||
| 035 | |a (NLM)36712674 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Di Pierro, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Quercetin as a possible complementary agent for early-stage COVID-19 |b Concluding results of a randomized clinical trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.02.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a ClinicalTrials.gov: NCT04861298 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023 Di Pierro, Khan, Iqtadar, Mumtaz, Chaudhry, Bertuccioli, Derosa, Maffioli, Togni, Riva, Allegrini, Recchia and Zerbinati. | ||
| 520 | |a Background: Quercetin, a natural polyphenol with demonstrated broad-spectrum antiviral, anti-inflammatory, and antioxidant properties, has been proposed as an adjuvant for early-stage coronavirus disease 2019 (COVID-19) infection. Objective: To explore the possible therapeutic effect of quercetin in outpatients with early-stage mild to moderate symptoms of COVID-19. Methods: This was an open-label randomized controlled clinical trial conducted at the department of medicine, King Edward Medical University, Lahore, PK. Patients were randomized to receive either standard of care (SC) plus an oral quercetin supplement (500 mg Quercetin Phytosome®, 1st week, TDS: 2nd week, BDS) (n = 50, quercetin group) or SC alone (n = 50, control group). Results: After one week of treatment, patients in the quercetin group showed a speedy recovery from COVID-19 as compared to the control group, i.e., 34 patients (vs. 12 in the control group) tested negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (p = 0.0004), and 26 patients (vs. 12 in the control group) had their COVID-19-associated acute symptoms resolved (p = 0.0051). Patients in the quercetin group also showed a significant fall in the serum lactate dehydrogenase (LDH) mean values i.e., from 406.56 ± 183.92 to 257.74 ± 110.73 U/L, p = 0.0001. Quercetin was well-tolerated by all the 50 patients, and no side effects were reported. Conclusion: Our results, suggest the possible therapeutic role of quercetin in early-stage COVID-19, including speedy clearance of SARS-CoV-2, early resolution of the acute symptoms and modulation of the host's hyperinflammatory response. Clinical Trial Registration: clinicaltrials.gov, identifier NCT04861298 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 3CL protease inhibition | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Natural Polyphenols | |
| 650 | 4 | |a Phytosome® | |
| 650 | 4 | |a Quercetin | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Khan, Amjad |e verfasserin |4 aut | |
| 700 | 1 | |a Iqtadar, Somia |e verfasserin |4 aut | |
| 700 | 1 | |a Mumtaz, Sami Ullah |e verfasserin |4 aut | |
| 700 | 1 | |a Chaudhry, Muhammad Nabeel Akbar |e verfasserin |4 aut | |
| 700 | 1 | |a Bertuccioli, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Derosa, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Maffioli, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Togni, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Riva, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Allegrini, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Recchia, Martino |e verfasserin |4 aut | |
| 700 | 1 | |a Zerbinati, Nicola |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in pharmacology |d 2010 |g 13(2022) vom: 23., Seite 1096853 |w (DE-627)NLM208568891 |x 1663-9812 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g day:23 |g pages:1096853 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fphar.2022.1096853 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |b 23 |h 1096853 | ||